Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03361358 · ClinicalTrials.gov registry record
Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma
A clinical trial, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- 44
- Enrollment target
NCT03361358: Completed study, sponsored by Agios Pharmaceuticals.
NCT03361358 is a clinical trial that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03361358 has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.
Primary Outcome
Number of tumor tissue samples found to have or not have MTAP deletion, as assessed by IHC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2019-09-30 |
What the finished NCT03361358 record still lists
NCT03361358 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03361358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03361358 about?
NCT03361358 is a clinical study titled "Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma". The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.
What is the current status of trial NCT03361358?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2018-03-01. Estimated completion is 2019-09-30.
Who is sponsoring clinical trial NCT03361358?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI